Literature DB >> 23861037

Long-term prognosis and risk factors among patients with HPV-associated oropharyngeal squamous cell carcinoma.

Brian M Lin1, Hao Wang, Gypsyamber D'Souza, Zhe Zhang, Carole Fakhry, Andrew W Joseph, Virginia E Drake, Giuseppe Sanguineti, William H Westra, Sara I Pai.   

Abstract

BACKGROUND: A subset of patients with human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (HPV-OSCC) experience poor clinical outcomes. The authors of this report explored prognostic risk factors for overall survival (OS) and recurrence-free survival (RFS).
METHODS: Patients with incident HPV-OSCC who received treatment at the Johns Hopkins Hospital between 1997 and 2008 and who had tissue available for HPV testing as well as demographic and clinicopathologic information (N = 176) were included. Tissue was tested for HPV by in situ hybridization (ISH) and/or p16 immunohistochemistry. Demographic and clinicopathologic information was extracted from medical records.
RESULTS: In total, 157 of 176 patients (90%) with OSCC had HPV-associated disease (HPV-OSCC). In the patients with HPV-OSCC, the 3-year and 5-year OS rates were 93% (95% confidence interval [CI], 88%-98%) and 89% (95% CI, 81%-97%), respectively. Shorter survival was observed among older patients (hazard ratio [HR], 2.33 per 10-year increase; 95% CI, 1.05-5.16 per 10-year increase; P = .038), patients with advanced clinical T classification (HR, 5.78; 95% CI, 1.60-20.8; P = .007), and patients who were currently using tobacco (HR, 4.38; 95% CI, 1.07-18.0; P = .04). Disease recurrence was associated with advanced clinical T-classification (HR, 8.32; 95% CI, 3.06-23; P < .0001), current/former alcohol use (HR, 13; 95% CI, 1.33-120; P = .03), and unmarried status (HR, 3.28; 95% CI, 1.20-9.00; P = .02). Patients who remained recurrence free for 5 years had an 8.6% chance of recurrence by 10 years (1-sided 95% CI upper bound, 19%; P = .088).
CONCLUSIONS: In this study, prognostic risk factors were identified for patients with HPV-OSCC. The observed recurrence rates between 5 years and 10 years after definitive therapy need to be validated in additional studies to determine whether extended cancer surveillance is warranted in this cancer population. Cancer 2013;119:3462-3471.. © 2013 American Cancer Society.
Copyright © 2013 American Cancer Society.

Entities:  

Keywords:  head and neck cancer; human papillomavirus; oropharyngeal cancer; risk factors; sex

Mesh:

Year:  2013        PMID: 23861037      PMCID: PMC3788050          DOI: 10.1002/cncr.28250

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  35 in total

1.  Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer.

Authors:  Arlene A Forastiere; Helmuth Goepfert; Moshe Maor; Thomas F Pajak; Randal Weber; William Morrison; Bonnie Glisson; Andy Trotti; John A Ridge; Clifford Chao; Glen Peters; Ding-Jen Lee; Andrea Leaf; John Ensley; Jay Cooper
Journal:  N Engl J Med       Date:  2003-11-27       Impact factor: 91.245

2.  Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck.

Authors:  Jay S Cooper; Thomas F Pajak; Arlene A Forastiere; John Jacobs; Bruce H Campbell; Scott B Saxman; Julie A Kish; Harold E Kim; Anthony J Cmelak; Marvin Rotman; Mitchell Machtay; John F Ensley; K S Clifford Chao; Christopher J Schultz; Nancy Lee; Karen K Fu
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

3.  Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer.

Authors:  Jacques Bernier; Christian Domenge; Mahmut Ozsahin; Katarzyna Matuszewska; Jean-Louis Lefèbvre; Richard H Greiner; Jordi Giralt; Philippe Maingon; Frédéric Rolland; Michel Bolla; Francesco Cognetti; Jean Bourhis; Anne Kirkpatrick; Martine van Glabbeke
Journal:  N Engl J Med       Date:  2004-05-06       Impact factor: 91.245

4.  The value of follow-up in patients treated for squamous cell carcinoma of the head and neck.

Authors:  M Boysen; O Lövdal; J Tausjö; F Winther
Journal:  Eur J Cancer       Date:  1992       Impact factor: 9.162

5.  Biological evidence that human papillomaviruses are etiologically involved in a subgroup of head and neck squamous cell carcinomas.

Authors:  V M van Houten; P J Snijders; M W van den Brekel; J A Kummer; C J Meijer; B van Leeuwen; F Denkers; L E Smeele; G B Snow; R H Brakenhoff
Journal:  Int J Cancer       Date:  2001-07-15       Impact factor: 7.396

6.  Deintensification candidate subgroups in human papillomavirus-related oropharyngeal cancer according to minimal risk of distant metastasis.

Authors:  Brian O'Sullivan; Shao Hui Huang; Lillian L Siu; John Waldron; Helen Zhao; Bayardo Perez-Ordonez; Ilan Weinreb; John Kim; Jolie Ringash; Andrew Bayley; Laura A Dawson; Andrew Hope; John Cho; Jonathan Irish; Ralph Gilbert; Patrick Gullane; Angela Hui; Fei-Fei Liu; Eric Chen; Wei Xu
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

7.  Evidence for a causal association between human papillomavirus and a subset of head and neck cancers.

Authors:  M L Gillison; W M Koch; R B Capone; M Spafford; W H Westra; L Wu; M L Zahurak; R W Daniel; M Viglione; D E Symer; K V Shah; D Sidransky
Journal:  J Natl Cancer Inst       Date:  2000-05-03       Impact factor: 13.506

8.  Involvement of intact HPV16 E6/E7 gene expression in head and neck cancers with unaltered p53 status and perturbed pRb cell cycle control.

Authors:  Tina Wiest; Elisabeth Schwarz; Christel Enders; Christa Flechtenmacher; Franz X Bosch
Journal:  Oncogene       Date:  2002-02-28       Impact factor: 9.867

9.  Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: a 9-year, 337-patient, multi-institutional experience.

Authors:  B Brockstein; D J Haraf; A W Rademaker; M S Kies; K M Stenson; F Rosen; B B Mittal; H Pelzer; B B Fung; M-E Witt; B Wenig; L Portugal; R W Weichselbaum; E E Vokes
Journal:  Ann Oncol       Date:  2004-08       Impact factor: 32.976

10.  A subset of head and neck squamous cell carcinomas exhibits integration of HPV 16/18 DNA and overexpression of p16INK4A and p53 in the absence of mutations in p53 exons 5-8.

Authors:  Harriet C Hafkamp; Ernst J M Speel; Annick Haesevoets; Fredrik J Bot; Winand N M Dinjens; Frans C S Ramaekers; Anton H N Hopman; Johannes J Manni
Journal:  Int J Cancer       Date:  2003-11-10       Impact factor: 7.396

View more
  26 in total

1.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

2.  Orbital mass as first presentation of metastatic p16-positive oropharyngeal squamous cell carcinoma.

Authors:  J Corbett; D Wilke; J Trites; N Lamond
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

3.  p16 immunohistochemistry in oropharyngeal squamous cell carcinoma: a comparison of antibody clones using patient outcomes and high-risk human papillomavirus RNA status.

Authors:  Jeremy Shelton; Bibianna M Purgina; Nicole A Cipriani; William D Dupont; Dale Plummer; James S Lewis
Journal:  Mod Pathol       Date:  2017-06-16       Impact factor: 7.842

Review 4.  Systematic Review of Tobacco Use after Lung or Head/Neck Cancer Diagnosis: Results and Recommendations for Future Research.

Authors:  Jessica L Burris; Jamie L Studts; Antonio P DeRosa; Jamie S Ostroff
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-08-17       Impact factor: 4.254

5.  Prognostic Implication of Persistent Human Papillomavirus Type 16 DNA Detection in Oral Rinses for Human Papillomavirus-Related Oropharyngeal Carcinoma.

Authors:  Eleni M Rettig; Alicia Wentz; Marshall R Posner; Neil D Gross; Robert I Haddad; Maura L Gillison; Carole Fakhry; Harry Quon; Andrew G Sikora; William J Stott; Jochen H Lorch; Christine G Gourin; Yingshi Guo; Weihong Xiao; Brett A Miles; Jeremy D Richmon; Peter E Andersen; Krzysztof J Misiukiewicz; Christine H Chung; Jennifer E Gerber; Shirani D Rajan; Gypsyamber D'Souza
Journal:  JAMA Oncol       Date:  2015-10       Impact factor: 31.777

6.  Multilevel Associations Between Patient- and Hospital-Level Factors and In-Hospital Mortality Among Hospitalized Patients With Head and Neck Cancer.

Authors:  Eric Adjei Boakye; Nosayaba Osazuwa-Peters; Betty Chen; Miao Cai; Betelihem B Tobo; Sai D Challapalli; Paula Buchanan; Jay F Piccirillo
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2020-05-01       Impact factor: 6.223

7.  Human papillomavirus genotype and oropharynx cancer survival in the United States of America.

Authors:  Marc T Goodman; Mona Saraiya; Trevor D Thompson; Martin Steinau; Brenda Y Hernandez; Charles F Lynch; Christopher W Lyu; Edward J Wilkinson; Thomas Tucker; Glenn Copeland; Edward S Peters; Sean Altekruse; Elizabeth R Unger
Journal:  Eur J Cancer       Date:  2015-11-18       Impact factor: 9.162

8.  Five-year relative survival for human papillomavirus-associated cancer sites.

Authors:  Hilda Razzaghi; Mona Saraiya; Trevor D Thompson; S Jane Henley; Laura Viens; Reda Wilson
Journal:  Cancer       Date:  2017-11-06       Impact factor: 6.860

Review 9.  Oropharyngeal squamous cell carcinoma treatment: current standards and future directions.

Authors:  Shanthi Marur; Barbara Burtness
Journal:  Curr Opin Oncol       Date:  2014-05       Impact factor: 3.645

10.  The mutational landscape of recurrent versus nonrecurrent human papillomavirus-related oropharyngeal cancer.

Authors:  R Alex Harbison; Mark Kubik; Eric Q Konnick; Qing Zhang; Seok-Geun Lee; Heuijoon Park; Jianan Zhang; Christopher S Carlson; Chu Chen; Stephen M Schwartz; Cristina P Rodriguez; Umamaheswar Duvvuri; Eduardo Méndez
Journal:  JCI Insight       Date:  2018-07-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.